Abstract
Summary
LPI (LP Information)' newest research report, the “Congestive Heart Failure (CHF) Industry Forecast” looks at past sales and reviews total world Congestive Heart Failure (CHF) sales in 2022, providing a comprehensive analysis by region and market sector of projected Congestive Heart Failure (CHF) sales for 2023 through 2029. With Congestive Heart Failure (CHF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Congestive Heart Failure (CHF) industry.
This Insight Report provides a comprehensive analysis of the global Congestive Heart Failure (CHF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Congestive Heart Failure (CHF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Congestive Heart Failure (CHF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Congestive Heart Failure (CHF) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Congestive Heart Failure (CHF).
The global Congestive Heart Failure (CHF) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Congestive Heart Failure (CHF) players cover Sanofi, Novartis, Pfizer, Merck & Co, AstraZeneca, GSK, Bristol-Myers Squibb, Mylan and Bausch Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Congestive Heart Failure (CHF) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Injection
Capsule
Tablets
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
Pfizer
Merck & Co
AstraZeneca
GSK
Bristol-Myers Squibb
Mylan
Bausch Health
Johnson & Johnson
Bayer
Boehringer Inhelheim
Exelixis
Lunan Pharmaceutical
Sinepharm
CRC
Hai Ni Pharmaceutical
Langtian
NCPC
Hayao
Xinhua Group
Xudong Haipu Pharmaceutical
This Insight Report provides a comprehensive analysis of the global Congestive Heart Failure (CHF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Congestive Heart Failure (CHF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Congestive Heart Failure (CHF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Congestive Heart Failure (CHF) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Congestive Heart Failure (CHF).
The global Congestive Heart Failure (CHF) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Congestive Heart Failure (CHF) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Congestive Heart Failure (CHF) players cover Sanofi, Novartis, Pfizer, Merck & Co, AstraZeneca, GSK, Bristol-Myers Squibb, Mylan and Bausch Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Congestive Heart Failure (CHF) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Injection
Capsule
Tablets
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
Pfizer
Merck & Co
AstraZeneca
GSK
Bristol-Myers Squibb
Mylan
Bausch Health
Johnson & Johnson
Bayer
Boehringer Inhelheim
Exelixis
Lunan Pharmaceutical
Sinepharm
CRC
Hai Ni Pharmaceutical
Langtian
NCPC
Hayao
Xinhua Group
Xudong Haipu Pharmaceutical
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Congestive Heart Failure (CHF) Market Size 2018-2029
2.1.2 Congestive Heart Failure (CHF) Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Congestive Heart Failure (CHF) Segment by Type
2.2.1 Injection
2.2.2 Capsule
2.2.3 Tablets
2.3 Congestive Heart Failure (CHF) Market Size by Type
2.3.1 Congestive Heart Failure (CHF) Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Congestive Heart Failure (CHF) Market Size Market Share by Type (2018-2023)
2.4 Congestive Heart Failure (CHF) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Congestive Heart Failure (CHF) Market Size by Application
2.5.1 Congestive Heart Failure (CHF) Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Congestive Heart Failure (CHF) Market Size Market Share by Application (2018-2023)
3 Congestive Heart Failure (CHF) Market Size by Player
3.1 Congestive Heart Failure (CHF) Market Size Market Share by Players
3.1.1 Global Congestive Heart Failure (CHF) Revenue by Players (2018-2023)
3.1.2 Global Congestive Heart Failure (CHF) Revenue Market Share by Players (2018-2023)
3.2 Global Congestive Heart Failure (CHF) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Congestive Heart Failure (CHF) by Regions
4.1 Congestive Heart Failure (CHF) Market Size by Regions (2018-2023)
4.2 Americas Congestive Heart Failure (CHF) Market Size Growth (2018-2023)
4.3 APAC Congestive Heart Failure (CHF) Market Size Growth (2018-2023)
4.4 Europe Congestive Heart Failure (CHF) Market Size Growth (2018-2023)
4.5 Middle East & Africa Congestive Heart Failure (CHF) Market Size Growth (2018-2023)
5 Americas
5.1 Americas Congestive Heart Failure (CHF) Market Size by Country (2018-2023)
5.2 Americas Congestive Heart Failure (CHF) Market Size by Type (2018-2023)
5.3 Americas Congestive Heart Failure (CHF) Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Congestive Heart Failure (CHF) Market Size by Region (2018-2023)
6.2 APAC Congestive Heart Failure (CHF) Market Size by Type (2018-2023)
6.3 APAC Congestive Heart Failure (CHF) Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Congestive Heart Failure (CHF) by Country (2018-2023)
7.2 Europe Congestive Heart Failure (CHF) Market Size by Type (2018-2023)
7.3 Europe Congestive Heart Failure (CHF) Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Congestive Heart Failure (CHF) by Region (2018-2023)
8.2 Middle East & Africa Congestive Heart Failure (CHF) Market Size by Type (2018-2023)
8.3 Middle East & Africa Congestive Heart Failure (CHF) Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Congestive Heart Failure (CHF) Market Forecast
10.1 Global Congestive Heart Failure (CHF) Forecast by Regions (2024-2029)
10.1.1 Global Congestive Heart Failure (CHF) Forecast by Regions (2024-2029)
10.1.2 Americas Congestive Heart Failure (CHF) Forecast
10.1.3 APAC Congestive Heart Failure (CHF) Forecast
10.1.4 Europe Congestive Heart Failure (CHF) Forecast
10.1.5 Middle East & Africa Congestive Heart Failure (CHF) Forecast
10.2 Americas Congestive Heart Failure (CHF) Forecast by Country (2024-2029)
10.2.1 United States Congestive Heart Failure (CHF) Market Forecast
10.2.2 Canada Congestive Heart Failure (CHF) Market Forecast
10.2.3 Mexico Congestive Heart Failure (CHF) Market Forecast
10.2.4 Brazil Congestive Heart Failure (CHF) Market Forecast
10.3 APAC Congestive Heart Failure (CHF) Forecast by Region (2024-2029)
10.3.1 China Congestive Heart Failure (CHF) Market Forecast
10.3.2 Japan Congestive Heart Failure (CHF) Market Forecast
10.3.3 Korea Congestive Heart Failure (CHF) Market Forecast
10.3.4 Southeast Asia Congestive Heart Failure (CHF) Market Forecast
10.3.5 India Congestive Heart Failure (CHF) Market Forecast
10.3.6 Australia Congestive Heart Failure (CHF) Market Forecast
10.4 Europe Congestive Heart Failure (CHF) Forecast by Country (2024-2029)
10.4.1 Germany Congestive Heart Failure (CHF) Market Forecast
10.4.2 France Congestive Heart Failure (CHF) Market Forecast
10.4.3 UK Congestive Heart Failure (CHF) Market Forecast
10.4.4 Italy Congestive Heart Failure (CHF) Market Forecast
10.4.5 Russia Congestive Heart Failure (CHF) Market Forecast
10.5 Middle East & Africa Congestive Heart Failure (CHF) Forecast by Region (2024-2029)
10.5.1 Egypt Congestive Heart Failure (CHF) Market Forecast
10.5.2 South Africa Congestive Heart Failure (CHF) Market Forecast
10.5.3 Israel Congestive Heart Failure (CHF) Market Forecast
10.5.4 Turkey Congestive Heart Failure (CHF) Market Forecast
10.5.5 GCC Countries Congestive Heart Failure (CHF) Market Forecast
10.6 Global Congestive Heart Failure (CHF) Forecast by Type (2024-2029)
10.7 Global Congestive Heart Failure (CHF) Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Congestive Heart Failure (CHF) Product Offered
11.1.3 Sanofi Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Congestive Heart Failure (CHF) Product Offered
11.2.3 Novartis Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Congestive Heart Failure (CHF) Product Offered
11.3.3 Pfizer Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Information
11.4.2 Merck & Co Congestive Heart Failure (CHF) Product Offered
11.4.3 Merck & Co Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Merck & Co Main Business Overview
11.4.5 Merck & Co Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Congestive Heart Failure (CHF) Product Offered
11.5.3 AstraZeneca Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 GSK
11.6.1 GSK Company Information
11.6.2 GSK Congestive Heart Failure (CHF) Product Offered
11.6.3 GSK Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 GSK Main Business Overview
11.6.5 GSK Latest Developments
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Information
11.7.2 Bristol-Myers Squibb Congestive Heart Failure (CHF) Product Offered
11.7.3 Bristol-Myers Squibb Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bristol-Myers Squibb Main Business Overview
11.7.5 Bristol-Myers Squibb Latest Developments
11.8 Mylan
11.8.1 Mylan Company Information
11.8.2 Mylan Congestive Heart Failure (CHF) Product Offered
11.8.3 Mylan Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Mylan Main Business Overview
11.8.5 Mylan Latest Developments
11.9 Bausch Health
11.9.1 Bausch Health Company Information
11.9.2 Bausch Health Congestive Heart Failure (CHF) Product Offered
11.9.3 Bausch Health Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Bausch Health Main Business Overview
11.9.5 Bausch Health Latest Developments
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Information
11.10.2 Johnson & Johnson Congestive Heart Failure (CHF) Product Offered
11.10.3 Johnson & Johnson Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Johnson & Johnson Main Business Overview
11.10.5 Johnson & Johnson Latest Developments
11.11 Bayer
11.11.1 Bayer Company Information
11.11.2 Bayer Congestive Heart Failure (CHF) Product Offered
11.11.3 Bayer Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Bayer Main Business Overview
11.11.5 Bayer Latest Developments
11.12 Boehringer Inhelheim
11.12.1 Boehringer Inhelheim Company Information
11.12.2 Boehringer Inhelheim Congestive Heart Failure (CHF) Product Offered
11.12.3 Boehringer Inhelheim Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Boehringer Inhelheim Main Business Overview
11.12.5 Boehringer Inhelheim Latest Developments
11.13 Exelixis
11.13.1 Exelixis Company Information
11.13.2 Exelixis Congestive Heart Failure (CHF) Product Offered
11.13.3 Exelixis Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Exelixis Main Business Overview
11.13.5 Exelixis Latest Developments
11.14 Lunan Pharmaceutical
11.14.1 Lunan Pharmaceutical Company Information
11.14.2 Lunan Pharmaceutical Congestive Heart Failure (CHF) Product Offered
11.14.3 Lunan Pharmaceutical Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lunan Pharmaceutical Main Business Overview
11.14.5 Lunan Pharmaceutical Latest Developments
11.15 Sinepharm
11.15.1 Sinepharm Company Information
11.15.2 Sinepharm Congestive Heart Failure (CHF) Product Offered
11.15.3 Sinepharm Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Sinepharm Main Business Overview
11.15.5 Sinepharm Latest Developments
11.16 CRC
11.16.1 CRC Company Information
11.16.2 CRC Congestive Heart Failure (CHF) Product Offered
11.16.3 CRC Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 CRC Main Business Overview
11.16.5 CRC Latest Developments
11.17 Hai Ni Pharmaceutical
11.17.1 Hai Ni Pharmaceutical Company Information
11.17.2 Hai Ni Pharmaceutical Congestive Heart Failure (CHF) Product Offered
11.17.3 Hai Ni Pharmaceutical Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Hai Ni Pharmaceutical Main Business Overview
11.17.5 Hai Ni Pharmaceutical Latest Developments
11.18 Langtian
11.18.1 Langtian Company Information
11.18.2 Langtian Congestive Heart Failure (CHF) Product Offered
11.18.3 Langtian Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Langtian Main Business Overview
11.18.5 Langtian Latest Developments
11.19 NCPC
11.19.1 NCPC Company Information
11.19.2 NCPC Congestive Heart Failure (CHF) Product Offered
11.19.3 NCPC Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 NCPC Main Business Overview
11.19.5 NCPC Latest Developments
11.20 Hayao
11.20.1 Hayao Company Information
11.20.2 Hayao Congestive Heart Failure (CHF) Product Offered
11.20.3 Hayao Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Hayao Main Business Overview
11.20.5 Hayao Latest Developments
11.21 Xinhua Group
11.21.1 Xinhua Group Company Information
11.21.2 Xinhua Group Congestive Heart Failure (CHF) Product Offered
11.21.3 Xinhua Group Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Xinhua Group Main Business Overview
11.21.5 Xinhua Group Latest Developments
11.22 Xudong Haipu Pharmaceutical
11.22.1 Xudong Haipu Pharmaceutical Company Information
11.22.2 Xudong Haipu Pharmaceutical Congestive Heart Failure (CHF) Product Offered
11.22.3 Xudong Haipu Pharmaceutical Congestive Heart Failure (CHF) Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Xudong Haipu Pharmaceutical Main Business Overview
11.22.5 Xudong Haipu Pharmaceutical Latest Developments
12 Research Findings and Conclusion